Clinical Trial Update: Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions

View source ↗

Summary

Clinical trial update indicates enrollment by invitation for a low-dose rapamycin study in Myalgic Encephalomyelitis and Long-COVID.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long Covid
• Myalgic Encephalomyelitis

Drugs mentioned

• Rapamycin (sirolimus)

Snippet

Sponsor: Simmaron Research Inc. | Conditions: Myalgic Encephalomyelitis, Long-COVID | Status: ENROLLING_BY_INVITATION